Fundraising Fox

CytomX Therapeutics

NASDAQ: CTMX

South San Francisco, US · Founded 2010 · Delaware corporation · 3 known investors

Clinical-stage biotechnology company developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment.

Biotech

Founders & leadership

SM
Sean McCarthyExecutive

Board

TSTim Shannon
Tim Shannonin𝕏Board directorGeneral Partner at Canaan Partners
EV
Elaine V. JonesBoard director
NENeil Exter
Neil ExterinBoard directorRetired Partner at Third Rock Ventures
FW
Frederick W. GluckBoard director
HH
Hoyoung HuhBoard director

Investors · 3

Longitude CapitalMenlo Park · $10M – $30M
Canaan PartnersreportedStamford · $500K – $20Mvia Tim Shannon · board
Third Rock VenturesreportedBoston · $100K – $5Mvia Neil Exter · board

Reported raises · per SEC filings

Form D private placements

$116.5M disclosed across 3 of 4 rounds · 2014–2026

▶$30MraisedAug 2023 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Chris OgdenExecutive Officer
  • Marcia BelvinExecutive Officer
  • James MeyersDirector
  • Alan AshworthDirector
  • Matthew YoungDirector
  • Jeff LandauExecutive Officer
  • Halley GilbertDirector
  • Wayne ChuExecutive Officer
  • Elaine JonesDirector
  • Mani MohindruDirector
  • Sean McCarthyExecutive Officer, Director
  • Lloyd RowlandExecutive Officer
Offering amount
$30M
Amount sold
$30M
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$70MraisedJun 2015 · 33 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rachel HumphreyDirector
  • Tim ShannonDirector
  • Frederick W. GluckDirector
  • Hoyoung HuhDirector
  • Elaine V. JonesDirector
  • Neil ExterDirector
  • Sean McCarthyExecutive Officer, Director
Offering amount
$70M
Amount sold
$70M
First sale
Jun 2015
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.5MraisedJan 2015 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tim ShannonDirector
  • Frederick W. GluckDirector
  • Elaine V. JonesDirector
  • Sean McCarthyExecutive Officer, Director
  • Neil ExterDirector
  • Hoyoung HuhDirector
Offering amount
$30M
Amount sold
$16.5M
First sale
Dec 2014
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

JPMorgan Chase & Co. Cuts CytomX Therapeutics (NASDAQ:CTMX) Price Target to $11.00 - Ticker Reporttickerreport.com · Aug 2026CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update - BioSpacebiospace.com · Aug 2026CytomX Therapeutics (CTMX) posts Q2 loss, expands Regeneron cancer pactstocktitan.net · Aug 2026CytomX Therapeutics (NASDAQ: CTMX) swings to Q2 loss, adds $37M Regeneron feestocktitan.net · Aug 2026Seven Fleet Capital Management LP Raises Stock Position in CytomX Therapeutics, Inc. $CTMXmarketbeat.com · Aug 2026CytomX Therapeutics Raises $234 Million in Equity Offering - TipRanks.comtipranks.com · Mar 2026

Frequently asked questions

What does CytomX Therapeutics do?
Clinical-stage biotechnology company developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment.
Who are CytomX Therapeutics's investors?
CytomX Therapeutics's investors include Longitude Capital, Canaan Partners, Third Rock Ventures.
How much funding has CytomX Therapeutics raised?
CytomX Therapeutics has disclosed $116.5M raised across 3 of its 4 known rounds.
Where is CytomX Therapeutics headquartered?
CytomX Therapeutics is headquartered in South San Francisco, US.